Fremanezumab Reduces Prolonged Sporadic Hemiplegic Migraine Rate

from TheBrief.Health · host TheBrief.Health

Fremanezumab, a CGRP-targeting preventive therapy, may reduce prolonged sporadic hemiplegic migraine attacks, offering a promising option for patients with stroke-like symptoms and limited disease-specific treatments.

Episode metadata supplied by the publisher feed · Published Mar 11, 2026

Embed this episode

Attribution link and audio player

NOW PLAYING

Fremanezumab Reduces Prolonged Sporadic Hemiplegic Migraine Rate

0:00 2:20

1×

No transcript for this episode yet

We transcribe on demand. Request one and we'll notify you when it's ready — usually under 10 minutes.

Share this episode

Similar Episodes

No similar episodes found.

Similar Podcasts

No similar podcasts found.

Frequently Asked Questions

How long is this episode of TheBrief.Health?

This episode is 2 minutes long.

When was this TheBrief.Health episode published?

This episode was published on March 11, 2026.

Can I download this TheBrief.Health episode?

Yes. Use the download control on the episode player to save the publisher-provided media file.

URL copied to clipboard!